1 / 32

CULTURING BORRELIA

CULTURING BORRELIA. A NEW GOLD STANDARD IN LYME BORRELIOSIS TESTING Joseph J. Burrascano Jr. M.D. DISCLAIMER STATEMENT. I am not an employee or direct consultant to any commercial or research laboratory I am a full time employee of Apogenics Inc. which has consulted with Advanced Labs

ima
Download Presentation

CULTURING BORRELIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CULTURING BORRELIA A NEW GOLD STANDARD IN LYME BORRELIOSIS TESTING Joseph J. Burrascano Jr. M.D.

  2. DISCLAIMER STATEMENT • I am not an employee or direct consultant to any commercial or research laboratory • I am a full time employee of Apogenics Inc. which has consulted with Advanced Labs • My compensation is not affected by sales at any of our clients, including Advanced Labs

  3. WHY IS LYME SUCH A DIFFICULT ILLNESS TO TREAT? • Diagnostic tests are a disaster- insensitive and indirect • Many patients with chronic multisystem illnesses that could be Lyme have negative or inconclusive serologies • No way to accurately assess whether treatment has cleared the infection • No way to know whether symptoms that persist or recur after treatment represent treatment failure or another process

  4. LITERATURE CITATIONS ON THE NEED FOR A BETTER TEST • Many cases of Lyme disease go undiagnosed and untreated, putting an infected patient at risk for developing a debilitating long-term illness (Liegner 1992, Klempner 2001, Dumber 2001, Nelson 2005, Augero 2005, Wormser 2006). • The signs and symptoms of disseminated Lyme disease are shared with many other diseases (Wormser2006). • Ahighly sensitive and specific assay for Borrelia sppis needed to assist in the accurate detection of these undiagnosed infections. (Augero 2005, Wormser 2006).

  5. SEROLOGIC TESTING IS INSENSITIVE All are based on only one or two lab strains! Low Sensitivity- • ELISA- Sensitivities range from 29% to 68% (Stricker, BMJ 2007; 335 (7628): 1008) • C6- ELISA assay- as bad as the standard ELISA • Western blot- sensitivities range from 46% to 50% for commercial kits (Goossens, Eur J ClinMicrobiol Infect Dis. 1999; 18: 551-560) and no more than 80% for reference tests (Donta, Clin Infect Dis. 2007; 44(8): 1134-1135) False positive IgMs in presence of EBV and Parvovirus (percentage unknown) Spinal tap- Only 9% have + CSF antibodies (Coyle, SUNY at Stony Brook) PARADOX- the more ill the patient, the weaker the serologic response and the LESS likely you are to get a positive test!

  6. SEROLOGIC TESTING IS NOT INFORMATIVE SEROLOGIES ARE INDIRECT TESTS- • Serologies do not detect an active infection, only prior exposure • Serologies may be non-reactive despite an active infection • Positive serologies may remain positive post treatment even if the infection has cleared • Are therefore are useless to assess treatment efficacy

  7. NUCLEIC ACID TESTING (PCR) • Sensitivities are low (no better than 30% for peripheral blood; slightly higher for synovial biopsy) • PCR Primers- Trade-off between sensitivity and specificity • Broad primer sets may include spirochetes other than pathogenic Borrelia • More focused primer sets may miss some important Bb strains • Solution requires doing a series of PCRs • Positive PCRs are often dismissed as “contaminated” • Can a positive PCR reflect “old” DNA, and not currently living Borrelia? • Not accepted as proof of infection by CDC or insurance carriers

  8. LITERATURE ON PROBLEMS WITH PCR • Attempts at using PCR have been disappointing in general (Wallach 1993, Nocton1996, Rauter2005, Augero 2005, Marques 2010). • Concerns over false positives have been raised (Klempner 2001, Klempner 2001, Molloy 2001).

  9. OTHER TECHNOLOGIES URINE ANTIGEN CAPTURE • Is a direct test of antigen spillage • Not known whether all pathogenic strains of Bb will be detected • Antigen spillage is not constant- may vary day to day • Sensitivity is low (30%), similar to PCR • Not accepted as proof of infection by CDC or insurance carriers T-CELL STIMULATION ASSAYS • Are several methods in use • Not known whether all pathogenic strains of Bb will be detected • No large scale clinical studies have been published on sensitivity and specificity • Apparently are significant numbers of false positives and false negatives • Also not accepted as proof of infection by CDC or insurance carriers

  10. WHY THESE PROBLEMS- 1 Borrelia have many variants Borrelia change over time Borrelia adapt to changing environments Borrelia contain a large amount of highly complex genetic material Clinical, wild-type Borrelia specimens are quite different from laboratory strains Borrelia have been very difficult to culture

  11. B. burgdorferi B. afzelii B. garinii B. spielmanii B. lonestari B. bissetti B. carolinensis B. americana B. andersonii B. kurtenbachii B. lusitaniae B. valaisiana B. sinica B. bavariensis B. japonica B. miyamoti B. yangtze B. tanukii B. turdi WHY THESE PROBLEMS- 2LYME- MORE THAN ONE SPIROCHETE

  12. WHY THESE PROBLEMS- 3BORRELIA: A CHANGELING Falsenfeld, 1971: Borrelia adapt to their local environment and vectors, and many new varieties and even genospecies arise: “Variations of Borrelia due to regional vectors could lead to new, as yet unseen forms of the disease.” Pachner, 1989: Experimentally infected a mouse and then isolated the Bb- the brain isolate was different from those in the blood. Presumably the different environment affected Bb gene expression, inducing a change in surface antigens. A similar change occurs as Bb passes from the tick into the human host.

  13. CULTURE:THE IDEAL LYME DISEASE TEST A reliable, sensitive, and specific direct test that can inform whether the patient is currently infected with live bacteria. • In other types of bacterial infections, typically a culture is taken, and growth indicates infection and possibly what specific bacterium is causing it. Examples include urine and throat cultures. • “For Lyme disease, a positive culture result would provide direct evidence of an active infection and would be beneficial to assess the accuracy of other diagnostic tests” (Auero-Rosenfeld 1996).

  14. CULTURING Bb-ADVANTAGES • Directly detects living Bb- if the patient’s culture is positive, then the patient had an active infection with Bb at the time the specimen was taken • Can be used for diagnosis • Can be used post-treatment to see whether the treatments have eliminated the infection • Can be designed to detect all relevant clinical strains of Borrelia, and not just lab strains • If combined with DNA sequencing, the exact identity of the Borrelia can be ascertained

  15. CULTURING Bb-DISADVANTAGES • Expensive • Peripheral blood only at this time • Large volume required • May take several weeks for Bb to grow • Overall, of all positives, 48% can be reported within first week; rest take 8-16 weeks • Must be off all antibiotics for at least four weeks prior to specimen collection • As with all blood cultures, may need several sets to be sure

  16. CULTURE SUCCESS!Now available for clinical use

  17. CONCEPT OF Bb AS A SYMBIONT EXPLAINS PREVIOUS CULTURE FAILURES TWO CLASSES OF SPIROCHETES: • Free-living (soil, ponds) • Symbionts (only exist within other living hosts) B. burgdorferi is a symbiont • Compared to free-living spirochetes, symbionts (T. pallidum and B. burgdorferi) have lost 80% of the genes necessary for free living (Margulis, Symbiosis, 2009; (47): 51-58)

  18. PREVIOUS Bb CULTURE FAILURES • Many culture efforts hit a dead end- Bb may remain viable for a period of time, but then stop dividing or divide slowly • Many of these later cultures contain only dead Borrelia, or altered forms of Bb, usually L-forms and cysts, possibly reflecting an insufficient growth environment • The key is to develop a culture system that has the nutrients and microenvironmental conditions that mimic what exists in animal and arachnid hosts

  19. OPTIMIZING CULTURE CONDITIONSDevelopment of mBSK • Began with BSK- proven track record and accepted • Many parameters were explored and optimized- • Collecting and transporting blood with and without culture media- must do both to maximize yield • Adding serum from antibiotic-free animals, and increasing the concentration • Optimizing culture conditions (full tubes, loose caps, CO2in the incubator because Bb is microaerophilic) • Use of two different culture tube sizes- must use both • Adding small concentrations of rifampin to prevent bacterial overgrowth • Adding DTT- a strong antioxidant

  20. THE RESULT: FAILURE! • Although spirochetes grew much more quickly and in increased numbers, after 10-14 days they converted into different morphological forms • All attempts to revert them back to spirochetal form failed regardless of the use of several different liquid media • In addition, several solid BSK-based media and PMR-agar media also failed • In summary, while modifications to BSK had a positive effect on the initial Borrelia cultures, additional parameters needed to be optimized to permit long-term Borreliagrowth

  21. WHAT EXISTS IN LIVING HOSTS THAT IS ABSENT FROM PREVIOUSLY USED CULTURE SYSTEMS? Many theories were considered and some were even attempted: • Sonicated Borrelia (should provide everything a culture medium might need) • Agar (old fashioned but useful in many bacterial cultures) • Alginate (major component of Borrelia biofilm) • Connective tissue components (Bb lives in joints) • Tick shell components (Bb lives in ticks for years) • Different composition of the tubes, dishes and slides • Different surface treatment of the tubes, dishes and slides • Others….

  22. PHYSICAL PREFERENCES OF Bb in vitro • Prefer to grow on a solid surface • Prefer frosted slides over smooth ones • Prefer glass over plastic • Collagen supports growth FINAL METHOD: • Begin with a starter culture in mBSK then after 6 days transfer into tubes that contain collagen-coated slides

  23. SUCCESS !!!! 94% sensitivity 100% specificity • Note that in mammals, Bb are most often found associated with collagen • Previous published reports showed maximal success rate in liquid media was 44% • Similar to results after day 6 • However, skin cultures had a maximal success rate of 88% • Similar to overall success rate of this system • the key may be that skin contains a large quantity of collagen

  24. HIGHLY SENSITIVE • Spiking experiments using lab strain B31: • Able to obtain positive cultures when as little as ONE Bb organism was added • Clinical specimens: • Some cultures demonstrated detectable growth in as little as SIX DAYS of culturing • Of all cultures that eventually became positive, 48% were positive at day 6

  25. VALIDATION STUDY 72 CDC-positive Lyme disease patients • 34 of the 72 cultures were positive after 6 days in culture (47%). • An additional 26 samples were positive at 8 weeks (83%) • At 16 weeks an additional 8 samples became positive (total 94%). • All samples stained positively with both polyclonal and monoclonal antibodies. • PCRs were positive for all the positive cultures (tested at either the 16SrDNA or CTP synthase loci- most were tested at both).

  26. SPECIFICITY 100% 48 negative controls: • All 48 negative control samples were negative by dark field microscopy and by anti-Borrelia monoclonal and polyclonal antibody staining at all time points examined (6 days, 8 weeks and 16 weeks; 100%). • Sequence analyses of each PCR product from the positive cultures confirmed that the DNA was derived from Borrelia, and sequencing showed a 93 to 100% similarity to B31/N40 strains of Bb. • Sequence variation was identified at the CTP synthase locus, suggesting that each sample was derived from an independent source and not from laboratory contamination.

  27. SEQUENCE TREE Figure 9. shows a neighbor-joining phylogenetic analysis of 600 bp alignment of the CTP synthase gene (pyrG) of the 51 Borrelia clinical isolates obtained from our validation study using MEGA 5 Evolutionary Genetics Analysis program [36]. Alphanumeric codes represent GenBank(NCBI) ID numbers. Nucleotide sequences for CTP synthase locus for 51 clinical isolates have the following sequential accession numbers: JX867374 through JX867424. Numbers at nodes indicate bootstrap support values (500 replicates).

  28. OPTIONS FOR THE PRACTITIONER Standard procedure: stain with polyclonal immunostain • Has been shown to detect B. burgdorferi s.s., B. garinii, B. afzelii and B. hermsii • Will not detect Treponema denticola May instead stain with a monoclonal • Will only detect Bb s.s., and not afzelii, garinii, or hermsii, nor will it detect T. denticola May add-on, to either of the above, DNA PCR combined with DNA sequencing • This allows a second layer of confirmation of the culture • This may also allow an earlier reported positive result, as PCRs are performed early on all specimens

  29. Bb CULTURE- NUTS AND BOLTS A POSITIVE CULTURE INDICATES THAT AN ACTIVE INFECTION WAS PRESENT AT THE TIME THE SPECIMEN WAS TAKEN • Cultures may be positive in an infected patient who is seronegative • A culture that is positive post treatment indicates ongoing infection • Culture positivity fulfills even the strict CDC surveillance case definition MY CLINICAL EXPERIENCE: • Highest sensitivity if the patient is symptomatic at the time of blood draw, and best to draw blood in early afternoon • Must not have been exposed to antibiotics for at least four weeks- six is better- prior to drawing the blood specimen • As with all blood cultures, may need several sets to be sure • Any positive test is diagnostic, even if it is the only positive out of a set of three

  30. ACTUAL CULTURE RESULTS

  31. CONCLUSIONS REMARKABLE, LANDMARK ACHIEVEMENT! • Able to identify Borreliaspecies; further species information is possible by adding a monoclonal immunostain • Is the most sensitive and specific test for Borrelia in human clinical samples currently available • Can be used for diagnosis, to indicate treatment efficacy, and can form the basis for a variety of future studies • HOWEVER, is only a laboratory tool. Clinical assessment will remain the primary informational tool for LLMDs. • Culturing should be utilized in thoughtfully designed clinical studies to generate meaningful data and to end the current reliance on anecdotal and uncontrolled reports

  32. Thank you! J. J. Burrascano Jr. M.D. New York

More Related